Pacira BioSciences, Inc. (PCRX): Price and Financial Metrics


Pacira BioSciences, Inc. (PCRX)

Today's Latest Price: $60.12 USD

0.73 (1.23%)

Updated Sep 30 6:55pm

Add PCRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

PCRX Stock Summary

  • With a one year PEG ratio of 533.05, Pacira BioSciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 93.43% of US stocks.
  • The price/operating cash flow metric for Pacira BioSciences Inc is higher than 95.38% of stocks in our set with a positive cash flow.
  • With a price/sales ratio of 6.29, Pacira BioSciences Inc has a higher such ratio than 80.38% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Pacira BioSciences Inc are YELP, AYX, GORO, KALA, and VIVE.
  • PCRX's SEC filings can be seen here. And to visit Pacira BioSciences Inc's official web site, go to www.pacira.com.
PCRX Daily Price Range
PCRX 52-Week Price Range

PCRX Stock Price Chart Technical Analysis Charts


PCRX Price/Volume Stats

Current price $60.12 52-week high $64.44
Prev. close $59.39 52-week low $27.46
Day low $58.67 Volume 461,500
Day high $60.87 Avg. volume 661,932
50-day MA $58.86 Dividend yield N/A
200-day MA $47.15 Market Cap 2.57B

Pacira BioSciences, Inc. (PCRX) Company Bio


Pacira Pharmaceuticals develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company was founded in 2006 and is based in Parsippany, New Jersey.

PCRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$60.12$7.01 -88%

Below please find a table outlining a discounted cash flow forecast for PCRX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Pacira BioSciences Inc ranked in the 12th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Pacira BioSciences Inc ended up being:

  • 87% of the company's capital comes from equity, which is greater than 71.6% of stocks in our cash flow based forecasting set.
  • The weighted average cost of capital for the company is 9. This value is greater than 73.04% stocks in the Healthcare sector that generate free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-89%
1%-88%
2%-88%
3%-88%
4%-88%
5%-88%

Want more companies with a valuation profile/forecast similar to that of Pacira BioSciences Inc? See LGND, BLFS, LMNX, STAA, and RGEN.


PCRX Latest News Stream


Event/Time News Detail
Loading, please wait...

PCRX Latest Social Stream


Loading social stream, please wait...

View Full PCRX Social Stream

Latest PCRX News From Around the Web

Below are the latest news stories about Pacira BioSciences Inc that investors may wish to consider to help them evaluate PCRX as an investment opportunity.

European advisory group backs Pacira pain med Exparel

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Pacira BioSciences' (PCRX) Exparel (bupivacaine liposome injectable suspension) for the treatment of postoperative pain.A final decision from the European Commission usually takes ~60 days....

Seeking Alpha | September 18, 2020

Pacira BioSciences's (PCRX) CEO David Stack on Q2 2020 Results - Earnings Call Transcript

Pacira BioSciences, Inc. (PCRX) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Susan Mesco – Head-Investor Relations Dave Stack – Chairman and Chief Executive Officer Charlie Reinhart – Chief Financial Officer Conference Call Participants Zach Sachar – Piper Sandler Randall Stanicky – RBC Capital Markets...

SA Transcripts on Seeking Alpha | August 8, 2020

Pacira to Report Second Quarter 2020 Financial Results on Thursday August 6, 2020

PARSIPPANY, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 6, 2020. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. To participate in the conference call, dial 1-877-845-0779 and provide the passcode 3276818. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com.For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-4...

Yahoo | July 30, 2020

Did Hedge Funds Make The Right Call On Pacira Biosciences Inc (PCRX)?

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | July 12, 2020

Pacira BioSciences, Inc. Announces Pricing of $350.0 Million Aggregate Principal Amount of 0.750% Convertible Senior Notes due 2025

Pacira BioSciences, Inc. (PCRX) today announced the pricing of $350.0 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $300.0 million aggregate principal amount of notes. Pacira also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $52.5 million aggregate principal amount of notes.

Yahoo | July 7, 2020

Read More 'PCRX' Stories Here

PCRX Price Returns

1-mo -3.41%
3-mo N/A
6-mo 95.19%
1-year 65.57%
3-year 59.05%
5-year 47.57%
YTD 32.72%
2019 5.30%
2018 -5.76%
2017 41.33%
2016 -57.94%
2015 -13.39%

Continue Researching PCRX

Want to see what other sources are saying about Pacira BioSciences Inc's financials and stock price? Try the links below:

Pacira BioSciences Inc (PCRX) Stock Price | Nasdaq
Pacira BioSciences Inc (PCRX) Stock Quote, History and News - Yahoo Finance
Pacira BioSciences Inc (PCRX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8059 seconds.